Patrick Arbuthnot to Liver
This is a "connection" page, showing publications Patrick Arbuthnot has written about Liver.
Connection Strength
2,922
-
Hepatic Delivery of Artificial Micro RNAs Using Helper-Dependent Adenoviral Vectors. Methods Mol Biol. 2016; 1364:249-60.
Score: 0,505
-
Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
Score: 0,453
-
Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther. 2009 Apr; 9(2):91-103.
Score: 0,316
-
Hepatitis B virus X protein does not influence essential steps of nucleotide excision repair effected by human liver extracts. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):806-10.
Score: 0,219
-
Nucleotide excision repair by extracts of human fetal hepatocytes. FEBS Lett. 2002 May 08; 518(1-3):144-8.
Score: 0,196
-
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
Score: 0,174
-
Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
Score: 0,163
-
Hepatitis B virus X-protein binds damaged DNA and sensitizes liver cells to ultraviolet irradiation. Biochem Biophys Res Commun. 1997 Mar 06; 232(1):255-60.
Score: 0,137
-
Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
Score: 0,123
-
Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015 Jul 10; 209:198-206.
Score: 0,120
-
Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
Score: 0,116
-
Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009 Oct 15; 125(8):1894-901.
Score: 0,082
-
Expression of c-erbA in human hepatocellular carcinomas. Anticancer Res. 1989 Jul-Aug; 9(4):885-7.
Score: 0,080
-
Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors. Oligonucleotides. 2007; 17(1):104-12.
Score: 0,068
-
In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
Score: 0,047
-
In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
Score: 0,042
-
Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
Score: 0,026
-
c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res. 1991 Mar-Apr; 11(2):921-4.
Score: 0,023
-
Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
Score: 0,017
-
Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004 May; 40(1):34-46.
Score: 0,014